Optimal management of the ICU: some problems and potential solutions
The costly critical care provided by highly qualified personnel using state-of-the-art equipment in today
The costly critical care provided by highly qualified personnel using state-of-the-art equipment in today
Currently both North America and more affluent areas of Europe are facing an increasing shortage of physicians in primary healthcare and in various hospital specialities, a shortage which in many of these countries is being alleviated by the excessively aggressive recruitment of foreign doctors. For example in the UK national health service, poor planning and under-investment in medical education has lead to a third of physicians now being recruited from overseas. Frequently these doctors are citizens of poorer EU nations or commonwealth countries in Africa and the Indian sub-continent that can ill afford to lose such expensively educated personnel. Yet sadly these poorer nations are now effectively subsidising the healthcare of the wealthy West. The UK is of course not alone in its reliance on foreign physicians- the same strategy has been employed in the US and Canada, as well as affluent EU countries such as Germany and Sweden. While the rights of individual workers to migrate should be protected, clearly health services in developed countries should be moving towards more ethical ways of solving their physician shortage.
The long-term solution is to increase the supply of domestically educated medical doctors, but policy makers could also consider ways of reducing the current demand on physicians by developing systems and work flows that allow other healthcare professionals and hospital workers to perform those tasks where the input of a doctor is not essential. Currently there are artificial barriers developed decades ago preventing highly educated healthcare workers from providing services that they are competent to offer. For instance specialist nurses and medical assistants could triage patients, order lab tests and either treat patients directly or refer them to doctors as necessary, and the bulk of a physician
In Europe prostate cancer (PCa) is currently the most commonly diagnosed cancer in men- around one in six in the West will eventually be diagnosed with the disease- but the majority of patients will die of unrelated causes. There are two major problems related to PCa diagnosis: firstly, because of the lack of a highly sensitive and specific biomarker, many elderly men without cancer, or with clinically insignificant tumours confined to the prostate gland, are still undergoing unnecessary biopsies. Secondly because of its random nature, the standard method of biopsy, the transrectal ultrasound biopsy (TRUS), frequently detects low risk cancers that do not need aggressive therapy but fails to detect many clinically significant tumours in the less accessible areas of the gland. Recent studies suggest that multiparametric MRI (mp-MRI) pre-biopsy, to identify suspicious areas, followed by targetted biopsy using MR-ultrasound fusion, which combines detailed MRI scans with real-time ultrasound images of the prostate, is the better approach.
One preliminary prospective cohort study reported last year was carried out at the US National Cancer Institute. During a seven year period more than 1000 men underwent mp-MRI followed by MR-ultrasound fusion and concurrent TRUS. Whole-gland pathology of the prostate was also carried out after any prostatectomies. It was found that MR-ultrasound fusion diagnosed 30% more high risk tumours and 17% fewer low-risk tumours than TRUS. However data are still needed on disease recurrence and PCa mortality, and the authors consider that random clinical trials should be carried out to determine eventual clinical outcomes. A retrospective analysis involving more than 600 Brazilian patients with suspected PCa was also reported recently with 286 patients undergoing MR-ultrasound fusion biopsies and 331 patients undergoing random ultrasound-guided biopsies. Again the former technique detected significantly more patients with high-risk cancer requiring surgery and significantly fewer low-risk tumours where only surveillance was needed. There are of course financial impacts of purchasing and using such technology, but improved patient risk stratification may well result in a negligible net cost increase.
Hopefully MR-ultrasound fusion can replace techniques such as TRUS for suspected PCa diagnosis, but a question still remains. Is it really always necessary to treat clinically significant PCa by radical prostatectomy or radiotherapy of the entire organ when erectile dysfunction, urinary incontinence and intestinal problems are such common side effects? Would it not be possible to utilize appropriate imaging technologies and confine treatment to the affected area of the gland?
This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.
Accept settingsHide notification onlyCookie settingsWe may ask you to place cookies on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience and to customise your relationship with our website.
Click on the different sections for more information. You can also change some of your preferences. Please note that blocking some types of cookies may affect your experience on our websites and the services we can provide.
These cookies are strictly necessary to provide you with services available through our website and to use some of its features.
Because these cookies are strictly necessary to provide the website, refusing them will affect the functioning of our site. You can always block or delete cookies by changing your browser settings and block all cookies on this website forcibly. But this will always ask you to accept/refuse cookies when you visit our site again.
We fully respect if you want to refuse cookies, but to avoid asking you each time again to kindly allow us to store a cookie for that purpose. You are always free to unsubscribe or other cookies to get a better experience. If you refuse cookies, we will delete all cookies set in our domain.
We provide you with a list of cookies stored on your computer in our domain, so that you can check what we have stored. For security reasons, we cannot display or modify cookies from other domains. You can check these in your browser's security settings.
.These cookies collect information that is used in aggregate form to help us understand how our website is used or how effective our marketing campaigns are, or to help us customise our website and application for you to improve your experience.
If you do not want us to track your visit to our site, you can disable this in your browser here:
.
We also use various external services such as Google Webfonts, Google Maps and external video providers. Since these providers may collect personal data such as your IP address, you can block them here. Please note that this may significantly reduce the functionality and appearance of our site. Changes will only be effective once you reload the page
Google Webfont Settings:
Google Maps Settings:
Google reCaptcha settings:
Vimeo and Youtube videos embedding:
.U kunt meer lezen over onze cookies en privacy-instellingen op onze Privacybeleid-pagina.
Privacy policy